Chen Ruyan, Tang Tian, Han Jianglong, Li Si, Liu Wenmin, Deng Haiyu, Jian Tingting, Fu Zhenming
Cancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Cancer Causes Control. 2025 May 13. doi: 10.1007/s10552-025-02007-1.
Significant advances in the management, in particular the treatment, of renal cell carcinoma (RCC) has have been made over the years. However, it is not clear whether these advances reduce the disease burden of RCC at the population level.
Using data from the Surveillance, Epidemiology, and End Results database, we estimated the temporal trends of RCC incidence, incidence-based mortality (IBM), and survival rates in the United States (US) from 1992 to 2019.
From 2008 to 2019, the incidence increased slowly at 1.1% annually (95% CI: 0.6% to 1.5%). The overall IBM rate of RCC increased by 6.8% per year (95% CI: - 1.1% to 15.3%) between 1994 and 1997, plateaued between 1997 and 2015, and then decreased nonsignificantly after 2015. During the study period, the overall Five year survival rate of RCC continuously increased from 53.69 in 1992 to 72.90% in 2014, with the best improvement observed for RCC patients with distant disease. However, we projected that, given the current trends, the incidence of RCC in the US will continue to increase from 6.92 per 100,000 in 2015-2019 to 9.59 per 100,000 in 2040-2044.
Over the years, the mortality of RCC has been decreased reducing at the US population level mainly because the considerably significantly improved survival of RCC patients at all stages through the advances in treatment. However, the overall incidence of RCC is continuously increasing, indicating that more effective preventive strategies should be developed to reduce the disease burden of RCC.
多年来，肾细胞癌（RCC）的管理，尤其是治疗方面取得了重大进展。然而，尚不清楚这些进展是否能在人群层面减轻RCC的疾病负担。
利用监测、流行病学和最终结果数据库的数据，我们估计了1992年至2019年美国RCC发病率、基于发病率的死亡率（IBM）和生存率的时间趋势。
2008年至2019年，发病率以每年1.1%的速度缓慢上升（95%CI：0.6%至1.5%）。1994年至1997年，RCC的总体IBM率每年上升6.8%（95%CI：-1.1%至15.3%），1997年至2015年趋于平稳，2015年后则无显著下降。在研究期间，RCC的总体五年生存率从1992年的53.69%持续上升至2014年的72.90%，远处转移疾病的RCC患者改善最为明显。然而，我们预测，按照当前趋势，美国RCC的发病率将继续从2015 - 2019年的每10万人6.92例增至 2040 - 2044年的每10万人9.59例。
多年来，RCC的死亡率在美国人群层面有所下降，这主要归功于治疗进展使各阶段RCC患者的生存率显著提高。然而，RCC的总体发病率持续上升，这表明应制定更有效的预防策略以减轻RCC的疾病负担。
